보건의료기술평가에서의 혁신과 가치

Abstract

After reviewing discussions on the values to consider in the reimbursement decision-making for medical technologies, it was found that most consider factors such as the extent of health enhancement, unmet need, robustness of evidence, and disease severity, among others. These align with the criteria considered in drug reimbursement decision-making in Korea. There’s an ongoing debate about acknowledging benefits beyond quality-adjusted life years (QALY). Still, there remains a lack of discussions and consensus on measuring and incorporating these additional benefits. While some countries introduced a new mechanism of action as one of the value elements, none solely attributed value to it. Instead, they used it as an additional criterion, alongside conditions indicating health improvement, to categorize innovative drugs. Additionally, most countries did not evaluate innovation solely based on input factors. A range of domestic and international discussions should be considered in the debate over acknowledging the value of innovation in Korea.